JBIO (Jade Biosciences) Valuation Rank


JBIO Jade Biosciences Inc JBIO
12 GF Score
Price $20.94
! 1 Warning Sign
View Full Analysis

What is Jade Biosciences Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Jade Biosciences Valuation Rank Related Terms

JBIO
12GF Score
Jade Biosciences Inc JBIO
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jade Biosciences Business Description

Address 221 Crescent Street, Building 23, Suite 105, Waltham, MA, USA, 02453
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
12GF Score

Get the complete analysis for JBIO

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.94
Price